Publications by authors named "Sharon Forsyth"

Claim this Profile
T
Thyroidectomy with or without postoperative radioiodine for patients with low-risk differentiated thyroid cancer in the UK (IoN): a randomised, multicentre, non-inferiority trial.
Ujjal Mallick, Kate Newbold, Matthew Beasley, Kate Garcez, Jonathan Wadsley, Sharon Forsyth

Lancet· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The IMRiS Trial: A Phase 2 Study of Intensity Modulated Radiation Therapy in Extremity Soft Tissue Sarcoma.
Beatrice Seddon, Franel Le Grange, Rita Simões, Chris Stacey, Shumona Shelly, Sharon Forsyth

Int J Radiat Oncol Biol Phys· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting radiotherapy response, Toxicities and quality-of-life related functional outcomes in soft tissue sarcoma of the extremities (PredicT) using dose-volume constraints development: a study protocol.
Rita Simões, Sarah Gulliford, Beatrice Seddon, Hakim-Moulay Dehbi, Martin Robinson, Sharon Forsyth

BMJ Open· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Prospective Observational Cohort Study for Newly Diagnosed Osteosarcoma Patients in the UK: ICONIC Study Initial Results.
Alexa Childs, Craig Gerrand, Bernadette Brennan, Robin Young, Kenneth S Rankin, Sharon L Forsyth

Cancers (Basel)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK.
Kenrick Ng, Rob Metcalf, Joseph Sacco, Anthony Kong, Graham Wheeler, Sharon Forsyth

BMJ Open· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PANTHER: AZD8931, inhibitor of EGFR, ERBB2 and ERBB3 signalling, combined with FOLFIRI: a Phase I/II study to determine the importance of schedule and activity in colorectal cancer.
David J Propper, Fangfei Gao, Mark P Saunders, Debashis Sarker, John A Hartley, Sharon Forsyth

Br J Cancer· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.
Laura Beaton, Henry F J Tregidgo, Sami A Znati, Sharon Forsyth, Nicholas Counsell

J Vasc Interv Radiol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial.
Peter J Hoskin, Kirsten Hopkins, Vivek Misra, Tanya Holt, Rhona McMenemin, Sharon Forsyth

Radiother Oncol· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer: The SCORAD Randomized Clinical Trial.
Peter J Hoskin, Kirsten Hopkins, Vivek Misra, Tanya Holt, Rhona McMenemin, Sharon Forsyth

JAMA· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VEROnA Protocol: A Pilot, Open-Label, Single-Arm, Phase 0, Window-of-Opportunity Study of Vandetanib-Eluting Radiopaque Embolic Beads (BTG-002814) in Patients With Resectable Liver Malignancies.
Laura Beaton, Henry F J Tregidgo, Sami A Znati, Sharon Forsyth, Matthew J Clarkson

JMIR Res Protoc· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Beatrice Seddon, Sandra J Strauss, Jeremy Whelan, Michael Leahy, Penella J Woll, Sharon Forsyth

Lancet Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer.
Peter Hoskin, Santhanam Sundar, Krystyna Reczko, Sharon Forsyth, Natasha Mithal

J Natl Cancer Inst· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.
Ujjal Mallick, Clive Harmer, Beng Yap, Jonathan Wadsley, Susan Clarke, Sharon Forsyth

N Engl J Med· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer.
Allan Hackshaw, Michael Roughton, Sharon Forsyth, Kathryn Monson, Krystyna Reczko

J Clin Oncol· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial.
Jack Cuzick, Ivana Sestak, Sarah E Pinder, Ian O Ellis, Sharon Forsyth

Lancet Oncol· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer.
Allan Hackshaw, Michael Baum, Tommy Fornander, Bo Nordenskjold, Antonio Nicolucci, Sharon Forsyth

J Natl Cancer Inst· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expression patterns of murine antichymotrypsin-like genes reflect evolutionary divergence at the Serpina3 locus.
Anita J Horvath, Sharon L Forsyth, Paul B Coughlin

J Mol Evol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Murine serpin 2A is a redox-sensitive intracellular protein.
Emma C Morris, Timothy R Dafforn, Sharon L Forsyth, Melinda A Missen, Anita J Horvath

Biochem J· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A review and comparison of the murine alpha1-antitrypsin and alpha1-antichymotrypsin multigene clusters with the human clade A serpins.
Sharon Forsyth, Anita Horvath, Paul Coughlin

Genomics· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis